Baumann F, Do D-D, Willenberg T, Baumgartner I, Diehm N
Department of Clinical and Interventional Angiology, Swiss Cardiovascular Center, Inselspital, University Hospital of Bern, Bern, Switzerland.
J Cardiovasc Surg (Torino). 2012 Aug;53(4):475-80.
The aim of this paper was to evaluate the efficacy of a novel 4-F compatible self-expanding Nitinol stent for the treatment of long femoro-popliteal obstructions.
This retrospective analysis includes patients with femoro-popliteal obstructions ≥ 120 mm in length, treated with a novel Nitinol stent (Pulsar-18) between February 2010 and December 2011. Patients were categorized as either intermittent claudication (IC) or critical limb ischemia (CLI). Primary endpoint was primary patency, secondary endpoints were target lesion revascularization (TLR).
A total of 31 patients (IC: N=18 and CLI: N=13) were included in the present series. Mean age was 73.3 ± 10.1 years and 71% (22/31) of the patients were male. Primary intervention was performed in 77.4% (24/31) of the patients and re-do revascularization in the remaining. Mean lesion length of femoro-popliteal obstructions was 163.5 ± 32.5 mm. Technical success was obtained in all patients. Mean follow-up duration was 316 ± 198 days. Primary patency rates were 83.3% in IC and 80.0% in CLI patients at 6 months and 64.1% and 54.9% at 12 months, respectively (P=0.84). Target lesion revascularization occurred in 5.6% of IC and 20.0% of CLI patients at 6 months and in 14.1% and 36.0% at 12 months, respectively (P=0.43).
Endovascular stenting of long femoro-popliteal lesions using the Pulsar-18 stent provides acceptable results with patency and restenosis rates comparable with data from literature for stenting of long femoro-popliteal obstructions.
本文旨在评估一种新型4-F兼容自膨式镍钛诺支架治疗长段股腘动脉闭塞的疗效。
本回顾性分析纳入了2010年2月至2011年12月间使用新型镍钛诺支架(Pulsar-18)治疗的股腘动脉闭塞长度≥120mm的患者。患者分为间歇性跛行(IC)或严重肢体缺血(CLI)。主要终点是原发通畅率,次要终点是靶病变血管重建(TLR)。
本系列共纳入31例患者(IC:n = 18,CLI:n = 13)。平均年龄为73.3±10.1岁,71%(22/31)的患者为男性。77.4%(24/31)的患者进行了初次干预,其余患者进行了再次血管重建。股腘动脉闭塞的平均病变长度为163.5±32.5mm。所有患者均获得技术成功。平均随访时间为316±198天。IC患者6个月时的原发通畅率为83.3%,CLI患者为80.0%;12个月时分别为64.1%和54.9%(P = 0.84)。IC患者6个月时靶病变血管重建发生率为5.6%,CLI患者为20.0%;12个月时分别为14.1%和36.0%(P = 0.43)。
使用Pulsar-18支架对长段股腘动脉病变进行血管内支架置入术可获得可接受结果,其通畅率和再狭窄率与文献中长段股腘动脉闭塞支架置入术的数据相当。